An observational study in Heart Failure With Reduced Ejection Fraction, sponsored by Cambridge Cardiac Care Centre. Status unknown at 1 site in Canada. Per ClinicalTrials.gov, last updated 2023-01-18.
Sponsored by Cambridge Cardiac Care Centre · Observational
The goal of this study is to test the impact of a virtual heart failure optimization program on uptake of guideline directed medical therapy, participation in cardiac rehabilitation \& impact on echocardiographic parameters.
This is a single center, prospective pre-post cohort study testing a virtual, multi-disciplinary heart failure optimization program for up-titration of guideline directed medical therapy. This nurse and kinesiologist-led program will start and up-titrate patients on GDMT and offer virtual cardiac rehabilitation over a 3-month period.
The investigators hypothesize that this program could safely achieve higher rates of maximally tolerated ARNI, Beta-blocker, MRA and SGLT2i rates, as well as participation in cardiac rehabilitation among HFrEF patient participants. The investigators hypothesize that participation will lead to improved Left Ventricular Ejection Fraction on Echocardiogram.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 400 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Cambridge Cardiac Care Centre is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults with HFrEF (ejection fraction less than 40%) with New York Heart Association (NYHA) class II or III symptoms
Exclusion Criteria:
Patients with HFrEF (LVEF\<40%) \& NYHA class II-III who are referred to and consent to participate in the "Virtual Heart Failure Optimization Program"
Other: Virtual Heart Failure Optimization Program
Participants referred to the "Virtual Heart Failure Optimization Program" will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation. Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well. All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming.
Change from baseline Doses of GDMT
Beta-blocker, ACE-inhibitor/Angiotensin receptor blocker/Valsartan-Sacubitril, Mineralocorticoid Receptor Antagonist, SGLT2 inhibitor
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular Ejection Fraction
Measured in Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline NYHA Classification
Stage of Heart Failure (I-IV, IV is worse)
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular Mass Index
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular End Diastolic Diameter
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Left Ventricular End Systolic Diameter
Measured by Transthoracic Echocardiogram
Time frame: After completion of program (3 months)
Change from baseline Serum Potassium
Time frame: After completion of program (3 months)
Change from baseline eGFR
Time frame: After completion of program (3 months)
Change from baseline Systolic Blood Pressure
Time frame: After completion of program (3 months)
Change from baseline Diastolic Blood Pressure
Time frame: After completion of program (3 months)
Change from baseline Heart Rate
Time frame: After completion of program (3 months)
Change from baseline Body Mass Index
Time frame: After completion of program (3 months)
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cambridge Cardiac Care Centre